Synta Pharmaceuticals Corp.
This article was originally published in Start Up
Executive Summary
Synta Pharmaceuticals Corp. isn't a traditional emerging biotech company. In fact, the firm is bucking many industry trends-it raised none of its $180 million from venture capitalists, developed each of its existing three drug candidates internally, and owns all the rights to its compounds. Further, notes Synta's co-founder, president and CEO, Safi Bahcall, PhD, the company has a productive, systems-driven drug discovery platform that will continue to feed its product pipeline.